Replimune Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $REPL in the last 30 days.
See all $REPL insider activity →Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 15, 2026, Replimune Group, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals, each of which is described
Replimune (REPL) and uniQure (QURE) shares rose 7% and 5% respectively after FDA Commissioner Marty Makary resigned. Makary's departure followed clashes with the Trump administration over e-cigarette authorizations. The FDA previously rejected REPL's melanoma therapy and changed feedback on QURE's Huntington's disease treatment.
The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning REPL (Replimune Group, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent REPL coverage spans regulation, corporate actions and market movers.
The increase in authorized shares could dilute existing equity if new shares are issued, but may also enable future financing.
Positive short-term price reaction to regulatory leadership change.
High‑priced melanoma therapy could drive significant revenue if adopted.
The positive panel vote suggests a higher probability of accelerated approval, supporting a sharp short‑term price rally.
The rejection and lawsuits increase regulatory and legal risk, likely pressuring the stock lower in the short term.
AlphAI scores every news story that mentions REPL with an AI model for sentiment and relevance, and aggregates insider trades from Replimune Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 15, 2026, Replimune Group, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals, each of which is described
1 min readReplimune (REPL) and uniQure (QURE) shares rose 7% and 5% respectively after FDA Commissioner Marty Makary resigned. Makary's departure followed clashes with the Trump administration over e-cigarette authorizations. The FDA previously rejected REPL's melanoma therapy and changed feedback on QURE's Huntington's disease treatment.
2 min readThe FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.
3 min readReplimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.
2 min readReplimune Group (REPL) faces securities class action lawsuits following the FDA's rejection of its RP1 Biologics License Application due to study design issues. The company will discuss its outlook at the Cantor Global Healthcare Conference. Analysts note increased regulatory and legal risks, with shares potentially trading above fair value.
2 min readReplimune (REPL) received FDA accelerated approval for its cancer therapy Tudriqev, despite staff concerns, after senior FDA leadership intervened. The Oncology Center of Excellence played a key role. Accelerated approval requires confirmatory trials. This marks a significant milestone for Replimune in the competitive oncology market.
2 min readReplimune Group Inc (REPL) hit a 52-week high of $16.20, up 165.99% over the past year. Analysts have mixed views, with price targets ranging from $14 to $24. The FDA's approval of its cancer treatment, TUDRIQEV, has drawn positive attention from analysts, with upgrades and increased price targets. The company's earnings report is anticipated to impact stock movement.
2 min readWedbush analyst Robert Driscoll raised Replimune Group's (REPL) price target to $9 from $6, maintaining a Neutral rating. The biotech company reported a fiscal year 2026 net loss of $313.9 million, with R&D and SG&A expenses increasing. The FDA accepted the resubmission of the BLA for RP1, setting a PDUFA goal date of August 2, 2026. The company's cash reserves decreased to $268.9 million as of March 31, 2026.
2 min readPresident Trump may fire FDA Commissioner Marty Makary, according to the Wall Street Journal. Several biotech and pharmaceutical companies, including Replimune (REPL), uniQure (QURE), Moderna (MRNA), and others, have publicly clashed with the FDA over drug-review processes. Shares of REPL, QURE, and MRNA rose 17%, 15%, and 10% respectively at the time of writing.
2 min readReplimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.
2 min read
